5 Most Promising Biotech Stocks to Buy Now

Page 5 of 5

1.  argenx SE (NASDAQ:ARGX)

On May 9, argenx SE (NASDAQ:ARGX) reported that the U.S. Food and Drug Administration approved a label expansion for Vyvgart and Vyvgart Hytrulo. It extended use across all serotypes of adult generalized myasthenia gravis, including anti-AChR, anti-MuSK, anti-LRP4, and triple seronegative patients.

On May 7, argenx SE (NASDAQ:ARGX) reported first-quarter 2026 financials, posting $1.3 billion in global product net sales, up 63% year over year, while flagging a May 10, 2026, PDUFA date for seronegative gMG. CEO Karen Massey said argenx “continues to deliver meaningful impact,” citing a 17th consecutive quarter of VYVGART growth and pointing to expansion across MG populations.

Argenx said it expects myositis topline data in the third quarter and MMN readouts in the fourth quarter of 2026 while advancing FcRn programs, including Phase 3-ready ARGX-213. Management added that it aims to treat 50,000 patients globally and secure 10 labeled signs by 2030, the company said.

argenx SE (NASDAQ:ARGX) is a global immunology company that works to improve the lives of people suffering from severe autoimmune diseases. It is operated in the United States, Japan, EMEA, and China.

While we acknowledge the potential of ARGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARGX and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen and 8 Best European Industrial Stocks to Buy Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 5 of 5